Kodiak Sciences (KOD) R&D Day 2024 summary

Clinical pipeline and development strategy

• Advancing three late-stage programs: Tarcocimab, KSI-501, and KSI-101, each targeting high-prevalence retinal diseases with significant unmet needs, leveraging the ABCD platform for enhanced durability and efficacy.

• Enhanced formulations address prior issues of immediacy deficit and cataract risk, combining conjugated and unconjugated proteins for improved onset, safety, and manufacturability.

• GLOW2 and DAYBREAK studies for Tarcocimab are actively enrolling, with top-line data expected in early to mid-2026; KSI-101 open-label data anticipated in early 2025.

• KSI-501, a first-in-class bispecific targeting VEGF and IL-6, is in Phase 3 and aims to address both vascular permeability and inflammation, with enhanced formulation for improved efficacy and durability.

• All programs leverage in-house technical leadership, commercial manufacturing capabilities, and a cash runway expected to support operations into 2026.

Market opportunity and commercial positioning

• The mainstay biologics market for retinal diseases exceeded $14 billion in 2023, with projections of $18 billion by 2028; each 1% market share could translate to $200–$300 million in net sales.

• Tarcocimab and KSI-501 are positioned as mainstay monotherapies with broad labels, targeting both treatment-naive and experienced patients, and offering flexible dosing intervals.

• Enhanced durability and efficacy are key differentiators, aiming to address the real-world gap between clinical trial dosing intervals and actual patient needs.

• Full global commercial rights and an approved high-volume manufacturing facility provide flexibility for commercialization and potential partnerships.

• KSI-101 targets a high unmet need in inflammatory retinal diseases, with potential for accelerated development and significant commercial upside in a greenfield segment.

Scientific and clinical insights

• Enhanced formulations combine conjugated and unconjugated proteins to improve both immediacy and durability, addressing prior trial shortcomings.

• Human PK data show Tarcocimab has a longer ocular half-life than current agents, supporting extended dosing intervals for a significant subset of patients.

• New trial designs use strict, OCT-based retreatment criteria to ensure optimal efficacy and real-world relevance.

• KSI-501’s dual mechanism targets both VEGF and IL-6, with early data suggesting potential for improved outcomes in subpopulations with high unmet need.

• KSI-101, lacking the bioconjugate, is formulated for high potency and rapid development in inflammatory retinal diseases, with accelerated pathways under consideration.